These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24128669)

  • 1. Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068.
    Zhou N; Nowicka-Sans B; McAuliffe B; Ray N; Eggers B; Fang H; Fan L; Healy M; Langley DR; Hwang C; Lataillade M; Hanna GJ; Krystal M
    J Antimicrob Chemother; 2014 Mar; 69(3):573-81. PubMed ID: 24128669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of virological response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-663068.
    Ray N; Hwang C; Healy MD; Whitcomb J; Lataillade M; Wind-Rotolo M; Krystal M; Hanna GJ
    J Acquir Immune Defic Syndr; 2013 Sep; 64(1):7-15. PubMed ID: 23614999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B'-infected patients.
    Charpentier C; Larrouy L; Visseaux B; Landman R; Levittas M; Storto A; Damond F; Yazdanpanah Y; Yeni P; Brun-Vézinet F; Descamps D
    J Antimicrob Chemother; 2012 Jun; 67(6):1459-61. PubMed ID: 22382470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of natural polymorphisms of HIV-1 non-group M on genotypic susceptibility to the attachment inhibitor fostemsavir.
    Alessandri-Gradt E; Charpentier C; Leoz M; Mourez T; Descamps D; Plantier JC
    J Antimicrob Chemother; 2018 Oct; 73(10):2716-2720. PubMed ID: 30032194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of amino acid changes associated with resistance to attachment inhibitor BMS-626529 in R5- and X4-tropic HIV-1 subtype B.
    Soulié C; Lambert-Niclot S; Fofana DB; Fourati S; Ait-Arkoub Z; Sayon S; Simon A; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2013 Jun; 68(6):1243-5. PubMed ID: 23396856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo patterns of resistance to the HIV attachment inhibitor BMS-488043.
    Zhou N; Nowicka-Sans B; Zhang S; Fan L; Fang J; Fang H; Gong YF; Eggers B; Langley DR; Wang T; Kadow J; Grasela D; Hanna GJ; Alexander L; Colonno R; Krystal M; Lin PF
    Antimicrob Agents Chemother; 2011 Feb; 55(2):729-37. PubMed ID: 21078948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors.
    Li Z; Zhou N; Sun Y; Ray N; Lataillade M; Hanna GJ; Krystal M
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4172-80. PubMed ID: 23774428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic barrier for attachment inhibitor BMS-626529 resistance in HIV-1 B and non-B subtypes.
    Fofana DB; Charpentier C; Maïga AI; Lambert-Niclot S; Sayon S; Désiré N; Simon A; Yazdanpanah Y; Katlama C; Descamps D; Calvez V; Marcelin AG; Soulié C
    J Antimicrob Chemother; 2015 Jan; 70(1):130-5. PubMed ID: 25270328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir.
    Lataillade M; Zhou N; Joshi SR; Lee S; Stock DA; Hanna GJ; Krystal M;
    J Acquir Immune Defic Syndr; 2018 Mar; 77(3):299-307. PubMed ID: 29206721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529.
    Landry I; Zhu L; Abu Tarif M; Hruska M; Sadler BM; Pitsiu M; Joshi S; Hanna GJ; Lataillade M; Boulton DW; Bertz RJ
    Antimicrob Agents Chemother; 2016 May; 60(5):2782-9. PubMed ID: 26902761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel class of HIV-1 inhibitors that targets the viral envelope and inhibits CD4 receptor binding.
    Wang HG; Williams RE; Lin PF
    Curr Pharm Des; 2004; 10(15):1785-93. PubMed ID: 15180540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of clinical envelopes with lack of sensitivity to the HIV-1 inhibitors temsavir and ibalizumab.
    Gartland M; Stewart E; Zhou N; Li Z; Rose R; Beloor J; Clark A; Tenorio AR; Krystal M
    Antiviral Res; 2024 Aug; 228():105957. PubMed ID: 38971430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155.
    Madani N; Perdigoto AL; Srinivasan K; Cox JM; Chruma JJ; LaLonde J; Head M; Smith AB; Sodroski JG
    J Virol; 2004 Apr; 78(7):3742-52. PubMed ID: 15016894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of primary resistance to HIV entry inhibitors among brazilian patients failing reverse transcriptase/protease inhibitors treatment reveal high prevalence of maraviroc resistance-related mutations.
    Alencar CS; Nishiya AS; Ferreira S; Giret MT; Diaz RS; Sabino EC
    AIDS Res Hum Retroviruses; 2010 Dec; 26(12):1267-71. PubMed ID: 20977300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects.
    Nettles RE; Schürmann D; Zhu L; Stonier M; Huang SP; Chang I; Chien C; Krystal M; Wind-Rotolo M; Ray N; Hanna GJ; Bertz R; Grasela D
    J Infect Dis; 2012 Oct; 206(7):1002-11. PubMed ID: 22896665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV gp120 H375 is unique to HIV-1 subtype CRF01_AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug.
    Schader SM; Colby-Germinario SP; Quashie PK; Oliveira M; Ibanescu RI; Moisi D; Mespléde T; Wainberg MA
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4257-67. PubMed ID: 22615295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gp120 substitutions at positions associated with resistance to fostemsavir in treatment-naive HIV-1-positive individuals.
    Lepore L; Fabrizio C; Bavaro DF; Milano E; Volpe A; Lagioia A; Angarano G; Saracino A; Monno L
    J Antimicrob Chemother; 2020 Jun; 75(6):1580-1587. PubMed ID: 32191306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients.
    Seclén E; González Mdel M; Lapaz M; Rodríguez C; del Romero J; Aguilera A; de Mendoza C; Soriano V; Poveda E
    J Antimicrob Chemother; 2010 Dec; 65(12):2502-4. PubMed ID: 20940179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab.
    Toma J; Weinheimer SP; Stawiski E; Whitcomb JM; Lewis ST; Petropoulos CJ; Huang W
    J Virol; 2011 Apr; 85(8):3872-80. PubMed ID: 21289125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unique Phenotypic Characteristics of Recently Transmitted HIV-1 Subtype C Envelope Glycoprotein gp120: Use of CXCR6 Coreceptor by Transmitted Founder Viruses.
    Ashokkumar M; Aralaguppe SG; Tripathy SP; Hanna LE; Neogi U
    J Virol; 2018 May; 92(9):. PubMed ID: 29491151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.